Evolution and governance of the biotechnology and pharmaceutical industry of China

被引:21
|
作者
Wang, Kai [2 ]
Hong, Jin [1 ]
Marinova, Dora [3 ]
Zhu, Liang [2 ]
机构
[1] Univ Sci & Technol China, Sch Management, Hefei 230026, Anhui, Peoples R China
[2] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei 230026, Anhui, Peoples R China
[3] Curtin Univ Technol, Curtin Univ Sustainabil Policy CUSP, Perth, WA 6845, Australia
基金
澳大利亚研究理事会; 中国国家自然科学基金;
关键词
Biotechnology and pharmaceutical industry; Evolution; Governance; Actor-Networks theory (ANT); INNOVATION; US;
D O I
10.1016/j.matcom.2008.09.001
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The high-speed growth of China's biotechnology industry during the past 20 years presents an excellent opportunity to examine its overall evaluation and governance from the perspective of science and technology policies. Although China's biotechnology industry has achieved tremendous extension both in scale and structure, the strengths it has gained from achievements in research and development activities have been significantly weakened in relation to processes of commercialization. After examining the definition of China's biotechnology industry as well as its evolution, the authors of this paper employ Actor-Networks Theory as a basic theoretical framework to reveal how China's biotechnology industry develops in the form of evolving networks within the country's social context and to identify what kinds of relationships exist among the relevant factors. Our hope is to provide guiding insights for improving the governance of China's biotechnology industry both in policy and in management practices. Crown Copyright (C) 2008 Published by Elsevier B.V. on behalf of IMACS. All rights reserved.
引用
收藏
页码:2947 / 2956
页数:10
相关论文
共 50 条
  • [1] Analysis on the Evolution and Governance of the Biotechnology Industry of China
    Wang, Kai
    Zhu, Liang
    Hong, Jin
    Marinova, Dora
    [J]. MODSIM 2007: INTERNATIONAL CONGRESS ON MODELLING AND SIMULATION: LAND, WATER AND ENVIRONMENTAL MANAGEMENT: INTEGRATED SYSTEMS FOR SUSTAINABILITY, 2007, : 2693 - 2699
  • [2] The evolution of the pharmaceutical-biotechnology industry
    Gottinger, Hans-Werner
    Umali, Celia L.
    [J]. BUSINESS HISTORY, 2008, 50 (05) : 583 - 601
  • [3] Governance inseparability and the evolution of US biotechnology industry
    Argyres, NS
    Liebeskind, JP
    [J]. JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION, 2002, 47 (02) : 197 - 219
  • [4] White biotechnology and pharmaceutical industry
    Sanchez Montero, Jose Maria
    [J]. ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA, 2007, 73 (02): : 501 - 535
  • [5] Modern biotechnology and pharmaceutical industry
    Cvak, L
    Fusek, M
    [J]. CHEMICKE LISTY, 2004, 98 (12): : 1087 - 1095
  • [6] BIOTECHNOLOGY AND THE PHARMACEUTICAL-INDUSTRY
    RUBIN, S
    [J]. CANCER INVESTIGATION, 1993, 11 (04) : 451 - 457
  • [7] BIOTECHNOLOGY IN THE PHARMACEUTICAL-INDUSTRY
    SENSI, P
    [J]. CHIMICA & L INDUSTRIA, 1986, 68 (1-2): : 56 - 61
  • [8] Editorial overview: Pharmaceutical biotechnology: Expanding horizons for pharmaceutical biotechnology in industry and academia
    de la Cueva-Mendez, Guillermo
    Seliktar, Dror
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2015, 35 : IV - VI
  • [9] THE PHARMACEUTICAL-INDUSTRY - IMPACTS OF BIOTECHNOLOGY
    DIBNER, MD
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1985, 6 (09) : 343 - 346
  • [10] Competitive collaboration in the pharmaceutical and biotechnology industry
    Bingham, Alph
    Ekins, Sean
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (23-24) : 1079 - 1081